JP2014530012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530012A5 JP2014530012A5 JP2014533413A JP2014533413A JP2014530012A5 JP 2014530012 A5 JP2014530012 A5 JP 2014530012A5 JP 2014533413 A JP2014533413 A JP 2014533413A JP 2014533413 A JP2014533413 A JP 2014533413A JP 2014530012 A5 JP2014530012 A5 JP 2014530012A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- pge
- cell
- stem cells
- retrovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 53
- 210000004027 cell Anatomy 0.000 claims description 35
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 32
- 210000000130 stem cell Anatomy 0.000 claims description 30
- 241001430294 unidentified retrovirus Species 0.000 claims description 25
- 102000008866 Prostaglandin E receptors Human genes 0.000 claims description 23
- 108010088540 Prostaglandin E receptors Proteins 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 21
- 150000003180 prostaglandins Chemical class 0.000 claims description 21
- 230000011664 signaling Effects 0.000 claims description 21
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims description 12
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 12
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 12
- 230000026683 transduction Effects 0.000 claims description 10
- 238000010361 transduction Methods 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 8
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 230000001177 retroviral effect Effects 0.000 claims description 5
- QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 claims description 4
- VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 claims description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 4
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 claims description 4
- 102000003964 Histone deacetylase Human genes 0.000 claims description 4
- 108090000353 Histone deacetylase Proteins 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 229930189037 Trapoxin Natural products 0.000 claims description 4
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 claims description 4
- 210000004165 myocardium Anatomy 0.000 claims description 4
- 230000002207 retinal effect Effects 0.000 claims description 4
- 210000002027 skeletal muscle Anatomy 0.000 claims description 4
- 108010060597 trapoxin A Proteins 0.000 claims description 4
- 108700001624 vesicular stomatitis virus G Proteins 0.000 claims description 4
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 4
- 229960000237 vorinostat Drugs 0.000 claims description 4
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 3
- 101000760602 Homo sapiens ATP-binding cassette sub-family D member 1 Proteins 0.000 claims description 3
- 108091027981 Response element Proteins 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000001919 adrenal effect Effects 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 102000047168 human ABCD1 Human genes 0.000 claims description 3
- 239000012212 insulator Substances 0.000 claims description 3
- 230000008488 polyadenylation Effects 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- 229960000604 valproic acid Drugs 0.000 claims description 3
- FMNQRUKVXAQEAZ-JNRFBPFXSA-N (5z,8s,9r,10e,12s)-9,12-dihydroxy-8-[(1s)-1-hydroxy-3-oxopropyl]heptadeca-5,10-dienoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H](O)[C@H]([C@@H](O)CC=O)C\C=C/CCCC(O)=O FMNQRUKVXAQEAZ-JNRFBPFXSA-N 0.000 claims description 2
- LLVVDFDWPQHXBA-QEJIITRLSA-N 11-Deoxy-16,16-dimethyl-PGE2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1CCC(=O)[C@@H]1C\C=C/CCCC(O)=O LLVVDFDWPQHXBA-QEJIITRLSA-N 0.000 claims description 2
- TUXFWOHFPFBNEJ-GJGHEGAFSA-N 13,14-dihydro-Delta(12)-prostaglandin J2 Chemical compound CCCCC[C@H](O)C\C=C1/[C@@H](C\C=C/CCCC(O)=O)C=CC1=O TUXFWOHFPFBNEJ-GJGHEGAFSA-N 0.000 claims description 2
- XSGQFHNPNWBVPT-DSFPJDRCSA-N 15-Methyl-15S-PGE2 Chemical compound CCCCC[C@](C)(O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XSGQFHNPNWBVPT-DSFPJDRCSA-N 0.000 claims description 2
- XSGQFHNPNWBVPT-VFXMVCAWSA-N 15-methyl-15R-PGE2 Chemical compound CCCCC[C@@](C)(O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XSGQFHNPNWBVPT-VFXMVCAWSA-N 0.000 claims description 2
- DXWJXQSQVUJRNS-YYWARMNLSA-N 16-Phenyl-tetranor-PGE2 Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H](C(=O)C[C@H]1O)C\C=C/CCCC(O)=O)C1=CC=CC=C1 DXWJXQSQVUJRNS-YYWARMNLSA-N 0.000 claims description 2
- XTNOEYFQXCQKLC-UHFFFAOYSA-N 18-(oxiren-2-yl)octadeca-15,17-dienoic acid Chemical compound C1=C(C=CC=CCCCCCCCCCCCCCC(=O)O)O1 XTNOEYFQXCQKLC-UHFFFAOYSA-N 0.000 claims description 2
- WTJYDBMHYPQFNJ-ZUVVJKHESA-N 19R-Hydroxy-PGE2 Chemical compound C[C@@H](O)CCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O WTJYDBMHYPQFNJ-ZUVVJKHESA-N 0.000 claims description 2
- RKHRWGLENCONFM-UHFFFAOYSA-N 2-hydroxyheptadeca-2,4,6-trienoic acid Chemical compound CCCCCCCCCCC=CC=CC=C(O)C(O)=O RKHRWGLENCONFM-UHFFFAOYSA-N 0.000 claims description 2
- NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 claims description 2
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 claims description 2
- WMLGLMGSFIXSGO-KTXJXPLISA-N 9-Deoxy-9-methylene-16,16-dimethyl -PGE2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=C)[C@@H]1C\C=C/CCCC(O)=O WMLGLMGSFIXSGO-KTXJXPLISA-N 0.000 claims description 2
- VKEJXDXJUFQESA-DLMPNJEASA-N 9-Deoxy-9-methylene-PGE2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=C)[C@@H]1C\C=C/CCCC(O)=O VKEJXDXJUFQESA-DLMPNJEASA-N 0.000 claims description 2
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 claims description 2
- 101800004538 Bradykinin Proteins 0.000 claims description 2
- 102400000967 Bradykinin Human genes 0.000 claims description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 2
- 108010002156 Depsipeptides Proteins 0.000 claims description 2
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 claims description 2
- 101710091045 Envelope protein Proteins 0.000 claims description 2
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 claims description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 2
- 229930188389 Lanatoside Natural products 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims description 2
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 claims description 2
- 101710188315 Protein X Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- YFGQJKBUXPKSAW-ZUDKKNPISA-N [(2r,3r,4s)-6-[(2r,3s,4s)-4-hydroxy-6-[(2r,3s,4s)-4-hydroxy-6-[[(3s,9s,10s,13r,17r)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2h-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-y Chemical compound O([C@H]1[C@@H](OC(C)=O)CC(O[C@@H]1C)O[C@H]1[C@@H](O)CC(O[C@@H]1C)O[C@H]1[C@@H](O)CC(O[C@@H]1C)O[C@@H]1CC2[C@]([C@@H]3C(C4(CC[C@@H]([C@@]4(C)CC3)C=3COC(=O)C=3)O)CC2)(C)CC1)C1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O YFGQJKBUXPKSAW-ZUDKKNPISA-N 0.000 claims description 2
- 210000001789 adipocyte Anatomy 0.000 claims description 2
- 210000000577 adipose tissue Anatomy 0.000 claims description 2
- 210000001130 astrocyte Anatomy 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 210000003651 basophil Anatomy 0.000 claims description 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims description 2
- 208000005980 beta thalassemia Diseases 0.000 claims description 2
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 claims description 2
- 229960002470 bimatoprost Drugs 0.000 claims description 2
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims description 2
- 210000003443 bladder cell Anatomy 0.000 claims description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 2
- 229950008654 butaprost Drugs 0.000 claims description 2
- UMMADZJLZAPZAW-OVXHCKHTSA-N carboprost tromethamine Chemical compound OCC([NH3+])(CO)CO.CCCCC[C@](C)(O)\C=C\[C@H]1[C@@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC([O-])=O UMMADZJLZAPZAW-OVXHCKHTSA-N 0.000 claims description 2
- 229960005296 carboprost tromethamine Drugs 0.000 claims description 2
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 claims description 2
- 229960001761 chlorpropamide Drugs 0.000 claims description 2
- 210000001612 chondrocyte Anatomy 0.000 claims description 2
- 230000002648 chondrogenic effect Effects 0.000 claims description 2
- 229960004409 cloprostenol Drugs 0.000 claims description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 2
- 108010027178 cyclic hydroxamic acid-containing peptide 1 Proteins 0.000 claims description 2
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 2
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 claims description 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 2
- 210000003979 eosinophil Anatomy 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 229960004979 fampridine Drugs 0.000 claims description 2
- 229960002602 fendiline Drugs 0.000 claims description 2
- 229950004346 gaboxadol Drugs 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 210000003897 hepatic stem cell Anatomy 0.000 claims description 2
- 210000003494 hepatocyte Anatomy 0.000 claims description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
- 229960002474 hydralazine Drugs 0.000 claims description 2
- 229960002240 iloprost Drugs 0.000 claims description 2
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 claims description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 2
- 229960004801 imipramine Drugs 0.000 claims description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 claims description 2
- 210000003292 kidney cell Anatomy 0.000 claims description 2
- 229940124280 l-arginine Drugs 0.000 claims description 2
- 229960001160 latanoprost Drugs 0.000 claims description 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 2
- 210000005265 lung cell Anatomy 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 210000003593 megakaryocyte Anatomy 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 claims description 2
- XRISENIKJUKIHD-LHQZMKCDSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e,4r)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentyl]heptanoate Chemical compound CCCC1([C@H](O)C\C=C\[C@@H]2[C@H](C(=O)C[C@H]2O)CCCCCCC(=O)OC)CCC1 XRISENIKJUKIHD-LHQZMKCDSA-N 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims description 2
- 229960005249 misoprostol Drugs 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 210000001178 neural stem cell Anatomy 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 229960001783 nicardipine Drugs 0.000 claims description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001597 nifedipine Drugs 0.000 claims description 2
- 210000004248 oligodendroglia Anatomy 0.000 claims description 2
- 210000000963 osteoblast Anatomy 0.000 claims description 2
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 claims description 2
- 229960005184 panobinostat Drugs 0.000 claims description 2
- 229960005152 pentetrazol Drugs 0.000 claims description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960003634 pimozide Drugs 0.000 claims description 2
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 claims description 2
- 239000000018 receptor agonist Substances 0.000 claims description 2
- 229940044601 receptor agonist Drugs 0.000 claims description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 2
- 210000004116 schwann cell Anatomy 0.000 claims description 2
- 229930182884 serinolamide Natural products 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 210000004927 skin cell Anatomy 0.000 claims description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 2
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 2
- 229940083618 sodium nitroprusside Drugs 0.000 claims description 2
- 229960002232 sodium phenylbutyrate Drugs 0.000 claims description 2
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 claims description 2
- DMRMZQATXPQOTP-GWTDSMLYSA-M sodium;(4ar,6r,7r,7as)-6-(6-amino-8-bromopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound [Na+].C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DMRMZQATXPQOTP-GWTDSMLYSA-M 0.000 claims description 2
- 210000002325 somatostatin-secreting cell Anatomy 0.000 claims description 2
- 229960003400 sulprostone Drugs 0.000 claims description 2
- UQZVCDCIMBLVNR-TWYODKAFSA-N sulprostone Chemical compound O[C@@H]1CC(=O)[C@H](C\C=C/CCCC(=O)NS(=O)(=O)C)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 UQZVCDCIMBLVNR-TWYODKAFSA-N 0.000 claims description 2
- 229960004458 tafluprost Drugs 0.000 claims description 2
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 claims description 2
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 claims description 2
- 229960004546 thiabendazole Drugs 0.000 claims description 2
- 235000010296 thiabendazole Nutrition 0.000 claims description 2
- 239000004308 thiabendazole Substances 0.000 claims description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 claims description 2
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims description 2
- 229950008081 unoprostone isopropyl Drugs 0.000 claims description 2
- 210000005167 vascular cell Anatomy 0.000 claims description 2
- 108010044267 Abnormal Hemoglobins Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000018126 Adrenomyeloneuropathy Diseases 0.000 claims 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims 1
- 229960002508 pindolol Drugs 0.000 claims 1
- BVTYOCKAKQQPEE-UHFFFAOYSA-N superphane Chemical compound C1=2CCC3=C4CCC=2C(=C2CC5)CCC4=C5C4=C3CCC1=C2CC4 BVTYOCKAKQQPEE-UHFFFAOYSA-N 0.000 claims 1
- MOILFCKRQFQVFS-UHFFFAOYSA-N 4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol Chemical compound C1C2C(C)(C)C1CC(O)C2(O)C MOILFCKRQFQVFS-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- ICLWTJIMXVISSR-UHFFFAOYSA-N gallamine Chemical compound CCN(CC)CCOC1=CC=CC(OCCN(CC)CC)=C1OCCN(CC)CC ICLWTJIMXVISSR-UHFFFAOYSA-N 0.000 description 1
- 229960003054 gallamine Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002571 pancreatic alpha cell Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- -1 phenyl ester Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 229960005032 treprostinil Drugs 0.000 description 1
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161541736P | 2011-09-30 | 2011-09-30 | |
| US61/541,736 | 2011-09-30 | ||
| PCT/US2012/057987 WO2013049615A1 (en) | 2011-09-30 | 2012-09-28 | Compounds for improved viral transduction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018017184A Division JP6745826B2 (ja) | 2011-09-30 | 2018-02-02 | 改善されたウイルスによる形質導入のための化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530012A JP2014530012A (ja) | 2014-11-17 |
| JP2014530012A5 true JP2014530012A5 (https=) | 2015-11-12 |
| JP6285863B2 JP6285863B2 (ja) | 2018-02-28 |
Family
ID=47996444
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014533413A Active JP6285863B2 (ja) | 2011-09-30 | 2012-09-28 | 改善されたウイルスによる形質導入のための化合物 |
| JP2018017184A Expired - Fee Related JP6745826B2 (ja) | 2011-09-30 | 2018-02-02 | 改善されたウイルスによる形質導入のための化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018017184A Expired - Fee Related JP6745826B2 (ja) | 2011-09-30 | 2018-02-02 | 改善されたウイルスによる形質導入のための化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9988644B2 (https=) |
| EP (4) | EP4095236A1 (https=) |
| JP (2) | JP6285863B2 (https=) |
| KR (1) | KR102011532B1 (https=) |
| CN (2) | CN103958667A (https=) |
| AU (1) | AU2012315699B2 (https=) |
| BR (1) | BR112014007782B1 (https=) |
| CA (1) | CA2850484C (https=) |
| CY (1) | CY1122654T1 (https=) |
| DK (2) | DK3269802T3 (https=) |
| EA (1) | EA032699B1 (https=) |
| ES (3) | ES2632444T5 (https=) |
| IL (2) | IL231812B (https=) |
| IN (1) | IN2014CN02518A (https=) |
| MX (2) | MX359398B (https=) |
| PT (2) | PT2760994T (https=) |
| SG (2) | SG11201401077PA (https=) |
| UA (1) | UA114796C2 (https=) |
| WO (1) | WO2013049615A1 (https=) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3031907T (pt) | 2008-11-06 | 2021-01-28 | Univ Indiana Res & Tech Corp | Materiais e métodos para melhorar procedimentos de enxerto de células estaminais hematopoiéticas |
| PT2760994T (pt) | 2011-09-30 | 2017-08-24 | Bluebird Bio Inc | Compostos para melhor transdução viral |
| ES2869701T3 (es) | 2012-08-01 | 2021-10-25 | United Therapeutics Corp | Tratamiento de hipertensión arterial pulmonar con células progenitoras endoteliales tratadas con prostaciclina |
| CA2880808C (en) | 2012-08-01 | 2023-01-24 | United Therapeutics Corporation | Treatment of pulmonary arterial hypertension with mesenchymal stem cells |
| US20150216903A1 (en) * | 2012-08-10 | 2015-08-06 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| SG11201504038XA (en) | 2012-11-27 | 2015-06-29 | Childrens Medical Center | Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction |
| JP6431850B2 (ja) | 2013-01-09 | 2018-11-28 | ユナイテッド セラピューティクス コーポレイション | プロスタサイクリンおよび間葉系幹細胞による脈管障害の処置 |
| ES2747951T3 (es) * | 2013-10-24 | 2020-03-12 | Ospedale San Raffaele Srl | Método |
| US20170173083A1 (en) * | 2014-03-26 | 2017-06-22 | The Brigham And Women's Hospital, Inc. | Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells |
| MX375592B (es) | 2014-04-25 | 2025-03-06 | The Children´S Medical Center Corp | Composiciones y su uso para tratar hemoglobinopatias. |
| ES2835861T5 (en) | 2015-05-08 | 2025-02-18 | Childrens Medical Ct Corp | Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction |
| RU2630654C2 (ru) * | 2015-07-29 | 2017-09-11 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Балтийский Федеральный Университет имени Иммануила Канта" (БФУ им. И. Канта) | Способ хемогенетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции астроцитов и нейронов |
| CN105062979A (zh) * | 2015-08-21 | 2015-11-18 | 昆明理工大学 | 一种培养戊型肝炎病毒的方法 |
| WO2017139561A1 (en) * | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| WO2017139576A1 (en) * | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| CN109415687A (zh) * | 2016-04-07 | 2019-03-01 | 蓝鸟生物公司 | 嵌合抗原受体t细胞组合物 |
| US10898494B2 (en) | 2016-05-05 | 2021-01-26 | Liquidia Technologies, Inc. | Dry powder treprostinil for the treatment of pulmonary hypertension |
| ES2927406T3 (es) | 2016-10-24 | 2022-11-04 | United Therapeutics Corp | Potenciación de las propiedades inmunomoduladoras de las MSC mediante treprostinil |
| EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
| SG11201908844YA (en) * | 2017-03-29 | 2019-10-30 | Bluebird Bio Inc | Vectors and compositions for treating hemoglobinopathies |
| US11261441B2 (en) | 2017-03-29 | 2022-03-01 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
| US11788087B2 (en) | 2017-05-25 | 2023-10-17 | The Children's Medical Center Corporation | BCL11A guide delivery |
| WO2019055814A2 (en) * | 2017-09-15 | 2019-03-21 | The Medical College Of Wisconsin, Inc. | EPOXYEICOSATRIENOIC ACID (EET) ANALOGUES TARGETING KIDNEYS |
| FR3074189A1 (fr) * | 2017-11-30 | 2019-05-31 | Assistance Publique - Hopitaux De Paris | Methode de generation de greffons de cellules souches hematopoietiques |
| CN110799641B (zh) * | 2018-04-13 | 2021-02-19 | 诺未科技（北京）有限公司 | 丁酸钠的用途及含有丁酸钠的培养体系 |
| CN109207427B (zh) * | 2018-09-17 | 2020-12-08 | 诺未科技（银川）有限公司 | 一种将人造血祖细胞转变为造血干细胞的方法 |
| EP3784695B1 (en) * | 2018-04-27 | 2023-08-09 | The Medical College of Wisconsin, Inc. | Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders |
| US12522811B2 (en) | 2018-05-01 | 2026-01-13 | The Children's Medical Center Corporation | Enhanced BCL11A RNP / CRISPR delivery and editing using a 3XNLS-CAS9 |
| US12350284B2 (en) | 2018-05-02 | 2025-07-08 | The Children's Medical Center Corporation | BCL11A microRNAs for treating hemoglobinopathies |
| WO2020056400A1 (en) | 2018-09-14 | 2020-03-19 | The Children's Hospital Of Philadelphia | Compositions and methods for hemoglobin production |
| KR20210076048A (ko) * | 2018-10-12 | 2021-06-23 | 라이프 테크놀로지스 코포레이션 | 조혈 줄기 및 전구 세포 확장 시스템 |
| WO2020111229A1 (ja) * | 2018-11-30 | 2020-06-04 | 国立大学法人京都大学 | 溶液を用いた薬物送達系 |
| WO2020264488A1 (en) * | 2019-06-28 | 2020-12-30 | The Children's Hospital Of Philadelphia | Compositions and methods for treating anemia |
| WO2021055801A1 (en) | 2019-09-18 | 2021-03-25 | The Medical College Of Wisconsin, Inc. | Improved alpha-galactosidase protein for enzyme replacement therapy (ert) and methods of use |
| AU2020365133A1 (en) * | 2019-10-16 | 2022-04-28 | Orchard Therapeutics (Europe) Limited | Compositions and methods for modifying eukaryotic cells |
| CA3163572A1 (en) * | 2020-05-27 | 2021-12-02 | Oleksandr PASTUKHOV | Novel transduction enhancers and uses thereof |
| KR20230019156A (ko) * | 2020-06-02 | 2023-02-07 | 카탈렌트 파마 솔루션즈, 엘엘씨 | 유전자 삽입을 위한 다수의 도크들이 있는 세포주 |
| CN115125270A (zh) * | 2021-03-22 | 2022-09-30 | 华东师范大学 | 一种α-珠蛋白过表达载体及其应用 |
| CN113106098B (zh) * | 2021-04-21 | 2022-04-01 | 贵州医科大学 | 一种在红系细胞中特异表达人β珠蛋白的重组序列及其应用 |
| AU2021202658A1 (en) | 2021-04-28 | 2022-11-17 | Fondazione Telethon | Gene therapy |
| CN113336833A (zh) * | 2021-06-04 | 2021-09-03 | 广州伯尼兹生物科技有限公司 | 一种高效分泌表达猪流行性腹泻病毒s1蛋白的生产方法 |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| GB202206346D0 (en) | 2022-04-29 | 2022-06-15 | Ospedale San Raffaele Srl | Gene therapy |
| WO2024033802A2 (en) | 2022-08-11 | 2024-02-15 | Fondazione Telethon Ets | Gene therapy |
| EP4602153A1 (en) | 2022-10-11 | 2025-08-20 | Fondazione Telethon ETS | 3d cell culture methods |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| KR20260016952A (ko) | 2023-05-23 | 2026-02-04 | 사나 바이오테크놀로지, 인크. | 탠덤 퓨소젠 및 관련 지질 입자 |
| IT202300011790A1 (it) | 2023-06-08 | 2024-12-08 | Fond Telethon Ets | Protocolli di manipolazione genica in cellule immunitarie |
| WO2025056970A1 (en) * | 2023-09-12 | 2025-03-20 | Virocell Biologics Ltd | Mammalian cell culture additives |
| IT202300022191A1 (it) | 2023-10-24 | 2025-04-24 | Fond Telethon Ets | Mezzi e metodi per la modifica genetica di uba1 |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| CN118436665A (zh) * | 2024-03-22 | 2024-08-06 | 浙大城市学院 | 一类三萜结构及其类似物及在制备抗病毒药物中的应用 |
| EP4640830A1 (en) | 2024-04-23 | 2025-10-29 | Fondazione Telethon ETS | Means and methods for safe and efficient gene editing in cells |
| WO2026003694A1 (en) * | 2024-06-24 | 2026-01-02 | Csl Behring Llc | Methods of enveloped virus transduction |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US568159A (en) | 1896-06-26 | 1896-09-22 | Veneering-machine | |
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
| ES2105262T3 (es) | 1992-05-18 | 1997-10-16 | Minnesota Mining & Mfg | Dispositivo de suministro de farmaco a traves de las mucosas. |
| WO1995000657A1 (en) | 1993-06-21 | 1995-01-05 | The Uab Research Foundation | Anti-sickling hemoglobin |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
| US5869039A (en) | 1993-10-15 | 1999-02-09 | Institut National De La Sante Et De La Recherche Medicale | X-linked adrenoleukodystrophy gene and corresponding protein |
| WO1996009385A1 (en) | 1994-09-19 | 1996-03-28 | Massachusetts Institute Of Technology | Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease |
| US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| JP4365456B2 (ja) * | 1995-09-29 | 2009-11-18 | インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション | ウイルス及び細胞結合部位を持つ分子を用いたウイルス媒介性ｄｎａ導入を増強する方法 |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6057117A (en) | 1996-04-04 | 2000-05-02 | Chiron Corporation | Identification and use of selective inhibitors of glycogen synthase kinase 3 |
| WO1998000541A2 (en) | 1996-07-03 | 1998-01-08 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of human disease |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| CA2346152A1 (en) | 1998-10-16 | 2000-04-27 | Novartis Ag | Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors |
| AU2183900A (en) | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
| US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
| AU770867B2 (en) | 1999-08-13 | 2004-03-04 | Fumie Sato | Prostaglandin derivatives |
| EP2292657A1 (en) | 1999-11-12 | 2011-03-09 | Baxter Biotech Technology S.A.R.L. | Reduced side-effect hemoglobin compositions |
| EP1237880B1 (en) | 1999-12-17 | 2008-01-23 | Novartis Vaccines and Diagnostics, Inc. | Pyrazine based inhibitors of glycogen synthase kinase 3 |
| IL141120A0 (en) | 2000-01-31 | 2002-02-10 | Pfizer Prod Inc | Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| ATE452972T1 (de) | 2001-05-01 | 2010-01-15 | Ca Nat Research Council | Induzierbares expressionssystem in eukaryotischen zellen |
| US20050163760A1 (en) | 2001-12-06 | 2005-07-28 | Nathalie Cartier-Lacave | Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders |
| GB2399819B (en) | 2001-12-24 | 2005-12-28 | Es Cell Int Pte Ltd | Method and lentiviral vector for transducing human embryonic stem cells |
| AU2003214920A1 (en) | 2002-02-04 | 2003-09-02 | Millennium Pharmaceuticals Inc. | Methods and compositions for treating hematological disorders |
| CA2496164C (en) | 2002-08-23 | 2010-11-09 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| DE60333487D1 (de) | 2002-12-13 | 2010-09-02 | Genetix Pharmaceuticals Inc | Therapeutische retrovirus-vektoren für gentherapie |
| AU2004227205B2 (en) | 2003-04-08 | 2010-06-10 | Yeda Research And Development Co. Ltd | Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same |
| ATE488252T1 (de) * | 2003-05-05 | 2010-12-15 | Virxsys Corp | Erhöhte transduktion mit abc- transportersubstratenhemmern |
| US6747037B1 (en) | 2003-06-06 | 2004-06-08 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| IL158868A0 (en) | 2003-11-13 | 2004-05-12 | Yeda Res & Dev | Methods of generating and using stem cells enriched with immature primitive progenitor |
| EP1760071A4 (en) | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF |
| AU2005299473B2 (en) | 2004-10-26 | 2012-06-28 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin EP4 agonists |
| US20080021078A1 (en) | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
| US20070087988A1 (en) | 2005-09-30 | 2007-04-19 | New York University | Hematopoietic progenitor kinase 1 for modulation of an immune response |
| US8076315B2 (en) | 2005-10-14 | 2011-12-13 | The Board Of Trustees Of The University Of Illinois | Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists |
| DE102005062741A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Fluorene und Carbazole als Liganden des EP2 Rezeptors |
| EP3424507A1 (en) | 2006-03-24 | 2019-01-09 | Children's Medical Center Corporation | Method to modulate hematopoietic stem cell growth |
| CA2650507A1 (en) * | 2006-04-27 | 2007-11-08 | Universite De Montreal | Assessment and reduction of risk of graft-versus-host disease |
| EP2049129B1 (en) | 2006-06-22 | 2013-06-12 | Yeda Research And Development Co., Ltd. | Catecholamine receptor modulation |
| EP2679221B1 (en) | 2006-10-20 | 2020-09-23 | Children's Medical Center Corporation | Method to enhance tissue regeneration |
| US9394520B2 (en) | 2006-12-08 | 2016-07-19 | University Of Rochester | Expansion of hematopoietic stem cells |
| ES2703592T3 (es) | 2007-03-07 | 2019-03-11 | Mei Pharma Inc | Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno |
| WO2008126932A2 (en) | 2007-04-09 | 2008-10-23 | Riken | Epigenetical regulation of brain plasticity |
| PT3031907T (pt) * | 2008-11-06 | 2021-01-28 | Univ Indiana Res & Tech Corp | Materiais e métodos para melhorar procedimentos de enxerto de células estaminais hematopoiéticas |
| EP2408444A4 (en) | 2009-03-19 | 2012-09-26 | Fate Therapeutics Inc | COMPOSITIONS WITH CYCLIC AMP AMPLIFIERS AND / OR EP LIGANDS, AND METHOD FOR THEIR PRODUCTION AND USE |
| US11459545B2 (en) * | 2009-11-15 | 2022-10-04 | Indiana University Research And Technology Corporation | Methods to enhance delivery and engraftment of stem cells including the identification of specific prostaglandin E2 receptors |
| PT2760994T (pt) | 2011-09-30 | 2017-08-24 | Bluebird Bio Inc | Compostos para melhor transdução viral |
| WO2014015318A1 (en) * | 2012-07-19 | 2014-01-23 | Bluebird Bio, Inc. | Soluble compounds for improved gene therapy methods |
| US20150216903A1 (en) * | 2012-08-10 | 2015-08-06 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| US9943545B2 (en) * | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
| ES2747951T3 (es) * | 2013-10-24 | 2020-03-12 | Ospedale San Raffaele Srl | Método |
| CN103937743B (zh) * | 2014-04-27 | 2017-12-01 | 浙江大学 | 一种利用三维诱导系统获得造血干细胞的方法 |
| US10669528B2 (en) * | 2015-06-25 | 2020-06-02 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| RU2018106515A (ru) * | 2015-07-21 | 2019-08-21 | Зе Чилдрен'С Медикал Сентер Корпорейшн | Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения |
| WO2017139561A1 (en) * | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| WO2017139576A1 (en) * | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| GB201706394D0 (en) * | 2017-04-21 | 2017-06-07 | Ospedale San Raffaele Srl | Gene Therapy |
| FR3074189A1 (fr) * | 2017-11-30 | 2019-05-31 | Assistance Publique - Hopitaux De Paris | Methode de generation de greffons de cellules souches hematopoietiques |
-
2012
- 2012-09-28 PT PT128365079T patent/PT2760994T/pt unknown
- 2012-09-28 PT PT171735673T patent/PT3269802T/pt unknown
- 2012-09-28 UA UAA201403867A patent/UA114796C2/uk unknown
- 2012-09-28 ES ES12836507T patent/ES2632444T5/es active Active
- 2012-09-28 DK DK17173567.3T patent/DK3269802T3/da active
- 2012-09-28 EP EP22161134.6A patent/EP4095236A1/en not_active Withdrawn
- 2012-09-28 ES ES19204363T patent/ES2913633T3/es active Active
- 2012-09-28 ES ES17173567T patent/ES2769270T3/es active Active
- 2012-09-28 DK DK12836507.9T patent/DK2760994T4/da active
- 2012-09-28 US US14/348,572 patent/US9988644B2/en active Active
- 2012-09-28 EP EP17173567.3A patent/EP3269802B1/en not_active Revoked
- 2012-09-28 EP EP12836507.9A patent/EP2760994B2/en active Active
- 2012-09-28 CN CN201280056851.7A patent/CN103958667A/zh active Pending
- 2012-09-28 CN CN201810168851.5A patent/CN108220246B/zh not_active Expired - Fee Related
- 2012-09-28 WO PCT/US2012/057987 patent/WO2013049615A1/en not_active Ceased
- 2012-09-28 IN IN2518CHN2014 patent/IN2014CN02518A/en unknown
- 2012-09-28 SG SG11201401077PA patent/SG11201401077PA/en unknown
- 2012-09-28 CA CA2850484A patent/CA2850484C/en active Active
- 2012-09-28 EA EA201490627A patent/EA032699B1/ru unknown
- 2012-09-28 SG SG10201602423TA patent/SG10201602423TA/en unknown
- 2012-09-28 EP EP19204363.6A patent/EP3656848B1/en active Active
- 2012-09-28 MX MX2014003923A patent/MX359398B/es active IP Right Grant
- 2012-09-28 AU AU2012315699A patent/AU2012315699B2/en not_active Ceased
- 2012-09-28 JP JP2014533413A patent/JP6285863B2/ja active Active
- 2012-09-28 KR KR1020147011495A patent/KR102011532B1/ko not_active Expired - Fee Related
- 2012-09-28 BR BR112014007782-7A patent/BR112014007782B1/pt not_active IP Right Cessation
-
2014
- 2014-03-30 IL IL231812A patent/IL231812B/en active IP Right Grant
- 2014-03-31 MX MX2018011791A patent/MX2018011791A/es unknown
-
2018
- 2018-02-02 JP JP2018017184A patent/JP6745826B2/ja not_active Expired - Fee Related
- 2018-06-04 US US15/997,643 patent/US10501759B2/en active Active
-
2019
- 2019-10-28 US US16/665,892 patent/US10907177B2/en active Active
-
2020
- 2020-01-22 CY CY20201100056T patent/CY1122654T1/el unknown
- 2020-12-17 US US17/125,930 patent/US11834668B2/en active Active
-
2021
- 2021-02-23 IL IL281045A patent/IL281045B/en unknown
-
2023
- 2023-11-30 US US18/525,721 patent/US20240229070A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530012A5 (https=) | ||
| US11834668B2 (en) | Compounds for improved viral transduction | |
| US20150216903A1 (en) | Compounds for improved viral transduction | |
| IL261002B1 (en) | Vcn enhancer compositions and methods of using the same | |
| WO2021046143A1 (en) | Cd24-associated particles and related methods and uses thereof | |
| JP2026010071A (ja) | 真核細胞を修飾するための組成物及び方法 | |
| JP2020511991A (ja) | ヘモグロビン異常症を治療するためのベクターおよび組成物 | |
| WO2014015318A1 (en) | Soluble compounds for improved gene therapy methods | |
| HK40117441A (en) | Vcn enhancer compositions and methods of using the same |